Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Wang

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology

English

OA08 Efficacy and Safety of Sintilimab Combined With 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit From Adjuvant Chemotherapy

Journal of Thoracic Oncology

English

OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

Journal of Thoracic Oncology

English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

P122 Survival Changes in Different Histologic Types of Lung Cancer: A Large Retrospective Cohort Analysis

Journal of Thoracic Oncology

English

ER Stress Signalling Through eIF2α and CHOP, but Not IRE1α, Attenuates Adipogenesis in Mice

English

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Wang

P018 Afatinib Named Patient Use Program in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

OA08 Efficacy and Safety of Sintilimab Combined With 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer

P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit From Adjuvant Chemotherapy

OA12.02 Updated Antitumor Activity of Crizotinib in Patients With MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

P1.15-17 Risk Factors of Local Recurrence in EGFR-Mutant Stage III-pN2 Adenocarcinoma After Complete Resection: A Multi-Center Real-World Cohort Study

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

P122 Survival Changes in Different Histologic Types of Lung Cancer: A Large Retrospective Cohort Analysis

ER Stress Signalling Through eIF2α and CHOP, but Not IRE1α, Attenuates Adipogenesis in Mice

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line